LiverMap®: the choice for screening the onset and progression of chronic liver conditions

Motivation: MRI methods for screening onset of fatty liver disease are lacking owing to the inability to isolate the earliest grades of inflammation, ballooning and fibrosis. Goal(s): To demonstrate the validity and reproducibility of liver multi-component relaxometry (LiverMap®) in screening onset of liver pathologies at both 1.5T and 3.0T. Approach: Patient cohorts comprised a validation cohort with 106 biopsy-proven MASLD patients and 16 healthy volunteers, and a reproducibility cohort of 30 volunteers with and without MASLD. Results: LiverMap® distinguished the onset of liver pathologies with AUROCs above 0.94, a repeatability CoV of 1.7%, and a reproducibility CoV of 3.5%. Impact: LiverMap® is a new approach to screen and monitor progression of chronic liver conditions in ~10 minutes scan time. In metabolic associated steatohepatitis, LiverMap® reliably distinguishes the onset of five key liver pathologies - fat, iron, inflammation, ballooning and fibrosis.